Emerging data suggest that molecular and epigenetic features—including CDKN2A deletion, TERT promoter mutation, copy number analyses, and methylation-based classification—will be important to integrate into risk stratification frameworks for meningioma.48–53. This evidence concerns the gene CDKN2A and meningioma.